What Is Myelodysplastic Syndrome (MDS) and How Do Families Plan for End of Life?
By CRYSTAL BAI •
The short answer: Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders characterized by impaired blood cell production and risk of transformation to acute myeloid leukemia (AML). High-risk MDS and MDS that has transformed to AML require careful palliative care and end-of-life planning.
Understanding MDS
MDS encompasses a spectrum of clonal bone marrow disorders characterized by cytopenias (anemia, neutropenia, thrombocytopenia) and dysplastic (abnormal) blood cell development. The IPSS-R (revised International Prognostic Scoring System) stratifies risk from very low to very high, guiding treatment decisions.
Treatment Options and Goals
Low-risk MDS: supportive care (transfusions, EPO), lenalidomide for 5q deletion, luspatercept. High-risk MDS: hypomethylating agents (azacitidine, decitabine), allogeneic stem cell transplant for eligible patients. When these fail, options are limited.
MDS Transformation to AML
Approximately 30% of MDS patients transform to AML, which has a poor prognosis in this context. Treatment-refractory MDS-AML may prompt conversations about hospice and comfort care — especially in older patients with significant comorbidities.
Transfusion Dependence and Quality of Life
Many MDS patients become transfusion-dependent — requiring regular red blood cell and platelet transfusions to maintain quality of life. End-of-life conversations often involve when to continue vs. stop transfusions, which require outpatient visits and have logistical implications for the final weeks of life.
End-of-Life Planning for MDS Families
MDS's often-slower trajectory — months to years — allows time for gradual advance care planning. Death doulas help families use this time intentionally, creating legacy projects and completing documents before cognitive or functional decline limits participation.
Frequently Asked Questions
Is MDS curable?
Low-risk MDS is managed but not cured; some high-risk MDS patients achieve long-term remission with allogeneic stem cell transplant. Most patients eventually experience disease progression.
When should MDS patients enroll in hospice?
Hospice is appropriate when curative or life-prolonging treatment is no longer the goal and life expectancy is 6 months or less. For MDS patients who have exhausted treatment options, hospice provides comfort-focused care including transfusion management.
Can a death doula help with MDS end-of-life planning?
Yes — death doulas support MDS patients and families through the often-gradual disease trajectory, helping with advance care planning, legacy work, and decisions about when to transition from active treatment to comfort care.
What happens when transfusions stop working for MDS?
When red blood cell transfusions no longer maintain adequate hemoglobin levels, or when transfusion frequency becomes burdensome, families may choose to stop this intervention and focus on comfort — a decision that benefits from advance care planning discussions.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.